Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Monoclonal Cyclin E1 Primary Antibody for IP - ABIN2689485
Keyomarsi, Herliczek: The role of cyclin E in cell proliferation, development and cancer. in Progress in cell cycle research 1998
Show all 4 Pubmed References
Mouse (Murine) Polyclonal Cyclin E1 Primary Antibody for FACS, IF (p) - ABIN670311
Xu, Zhang, Li, Li, Zhang: Concentration-Dependent Diversifcation Effects of Free Cholesterol Loading on Macrophage Viability and Polarization. in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2015
Human Polyclonal Cyclin E1 Primary Antibody for ELISA - ABIN97973
Simone, Resta, Bagella, Giordano, Guanti: Cyclin E and chromosome instability in colorectal cancer cell lines. in Molecular pathology : MP 2002
Human Polyclonal Cyclin E1 Primary Antibody for ELISA, WB - ABIN560214
Hudelist, Singer, Pischinger, Kaserer, Manavi, Kubista, Czerwenka: Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. in Proteomics 2006
Human Polyclonal Cyclin E1 Primary Antibody for IF (p), IHC (p) - ABIN1713477
Wang, Wang: Studying the relationship between cell cycle and Alzheimer's disease by gold nanoparticle probes. in Analytical biochemistry 2015
Human Polyclonal Cyclin E1 Primary Antibody for ICC, IF - ABIN4301619
Fu, Kohaar, Moore, Lenz, Figueroa, Tang, Porter-Gill, Chatterjee, Scott-Johnson, Garcia-Closas, Muchmore, Baris, Paquin, Ylaya, Schwenn, Apolo, Karagas, Tarway, Johnson, Mumy, Schned, Guedez, Jones et al.: The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. ... in Cancer research 2014
Human Polyclonal Cyclin E1 Primary Antibody for IP, ELISA - ABIN2473143
Premack, Gardner: Role of ion channels in lymphocytes. in Journal of clinical immunology 1992
Show all 2 Pubmed References
in a series of human biopsies, non-metastatic SCCs displayed a higher degree of chromosomal alterations and higher expression of the S phase regulator Cyclin E and the DNA damage signal gammaH2AX (show H2AFX Antibodies) than the less aggressive, non-squamous, basal cell carcinomas. However, metastatic Squamous cell carcinoma lost the gammaH2AX (show H2AFX Antibodies) signal and Cyclin E, or accumulated cytoplasmic Cyclin E.
Cytoplasmic cyclin E identifies patients with the highest likelihood of recurrence consistently across different patient cohorts and subtypes. These patients may benefit from alternative therapies targeting the oncogenic isoforms of cyclin E.
our results validate the assumption that CBX7 (show CBX7 Antibodies) is a tumor suppressor of gliomas. Moreover, CBX7 (show CBX7 Antibodies) is a potential and novel prognostic biomarker in glioma patients. We also clarified that CBX7 (show CBX7 Antibodies) silences CCNE1 via the combination of CCNE1 promoter and the recruitment of HDAC2 (show HDAC2 Antibodies).
Our findings suggest that gene copy-number gain and upregulation of CCNE1 occur in ovarian clear cell carcinoma and are associated with a worse clinical outcome, dictating the survival of early-stage patients.
YAP (show YAP1 Antibodies)/ TAZ (show TAZ Antibodies) pathways contribute to the proliferation/quiescence switch during colon cancer 5FU treatment according to the concerted regulation of Cyclin E1 and CREB (show CREB1 Antibodies)
Silencing of CDCA5 (show CDCA5 Antibodies) suppresses proliferation of gastric cancer cells by inducing G1-phase arrest via downregulating CCNE1.
Analysis of genomic data from TCGA demonstrated coamplification of CCNE1 and AKT2 (show AKT2 Antibodies) Overexpression of Cyclin E1 and AKT (show AKT1 Antibodies) isoforms, in addition to mutant TP53 (show TP53 Antibodies), imparted malignant characteristics in untransformed fallopian tube secretory cells, the dominant site of origin of high-grade serous ovarian cancer
Finding suggest that amplification of CCNE1 serves as one mechanism for the development of some serous tubal intraepithelial carcinomas.
Prognostic gene sets based on the 13 genes were developed, and their prognostic values were verified in three independent patient cohorts (n=501). Among them, a signature of CCNE1 and its coexpressed genes was significantly associated with disease progression and validated in the independent cohorts.
Cyclin E1 mRNA and protein expressions were suppressed.
These results demonstrate a repressor role for NFAT1 (show NFAT1 Antibodies) in cell cycle progression and Cyclin E expression in B lymphocytes, and suggest a potential function for NFAT1 (show NFAT1 Antibodies) protein in B cell malignancies.
This approach allowed us to determine the identity of cyclin E protein partners, as well as phosphorylation substrates of cyclins E (cyclin (show PCNA Antibodies) E1and cyclin E2 (show CCNE2 Antibodies))and its associated kinase, Cdk2 (show CDK2 Antibodies), in different mouse organs.
inhibition of PDK4 (show PDK4 Antibodies) activity in Hepatocellular carcinoma cells increased cyclin E1, cyclin A2 (show CCNA2 Antibodies), and E2F1 (show E2F1 Antibodies) proteins.
Spermatocytes lacking cyclin E2 (show CCNE2 Antibodies) and one E1 allele (E1+/-E2-/-) displayed a high rate of telomere abnormalities but can progress to pachytene and diplotene stages.
NF-kappaB (show NFKB1 Antibodies)-miR (show MLXIP Antibodies)-195/497-Igf1r (show IGF1R Antibodies)/Insr (show INSR Antibodies)-Ccnd2 (show CCND2 Antibodies)/Ccne1 plays important roles in myogenesis.
Myb (show MYB Antibodies) regulates Cyclin E1 expression in normal gastrointestinal tract epithelial cells and is required during intestinal tumorigenesis
These results highlight a new role for E-type cyclins (Ccne1 and Ccne2 (show CCNE2 Antibodies)) as important regulators of male meiosis.
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 (show CDK2 Antibodies) in hepatocytes inhibits DNA replication and liver regeneration in mice.
Superoxide dismutase (show SOD1 Antibodies) induces G1-phase cell cycle arrest by down-regulated expression of Cdk-2 (show CDK2 Antibodies) and cyclin-E in sarcoma tumor cells.
Ablation of cyclin E led to a decreased number of synapses, reduced number and volume of dendritic spines, and resulted in impaired synaptic plasticity and memory formation.
miR (show MYLIP Antibodies)-15/16 and CPEB co-regulate cyclin E1 mRNA.
cyclin E is dynamically and highly conjugated to SUMO2 (show SUMO2 Antibodies)/3 on chromatin, independently of Cdk2 (show CDK2 Antibodies) activity and origin activation.
These results show that cyclin E destruction at the midblastula transition requires both phosphorylation and nuclear import, as well as proteasomal activity.
intestinal clock controls the expression of key cell cycle regulators, such as cdc2 (show CDK1 Antibodies), wee1 (show WEE1 Antibodies), p21 (show CDKN1A Antibodies), PCNA (show PCNA Antibodies) and cdk2 (show CDK2 Antibodies), but only weakly influences cyclin B1 (show CCNB1 Antibodies), cyclin B2 (show CCNB2 Antibodies) and cyclin E1 expression.
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK2, whose activity is required for cell cycle G1/S transition. This protein accumulates at the G1-S phase boundary and is degraded as cells progress through S phase. Overexpression of this gene has been observed in many tumors, which results in chromosome instability, and thus may contribute to tumorigenesis. This protein was found to associate with, and be involved in, the phosphorylation of NPAT protein (nuclear protein mapped to the ATM locus), which participates in cell-cycle regulated histone gene expression and plays a critical role in promoting cell-cycle progression in the absence of pRB. Two alternatively spliced transcript variants of this gene, which encode distinct isoforms, have been described. Two additional splice variants were reported but detailed nucleotide sequence information is not yet available.
, G1/S-specific cyclin-E1
, G1/S-specific cyclin-E1-like
, g1/S-specific cyclin-E1-like
, cyclin Es
, cyclin Et
, cyclin E
, G1/S-specific cyclin-E2
, G1/S-specific cyclin-E3
, cyclin E3